Sanara MedTech Inc.

Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanara MedTech (SMTI) reports record revenue in 2022, eyes market expansion

Sanara MedTech had a strong financial performance in 2022, despite increased expenses leading to a higher net loss. The company is strategically positioned to capitalize on opportunities in the Surgical Wound Care market and leverage partnerships for growth.

Sanara MedTech Inc. reports robust revenue growth and strategic advancements

Sanara MedTech Inc. demonstrated strong revenue growth and cost management in Q1 2023, with a focus on FDA clearances and product commercialization.
While facing supply challenges with Allocyte, the company's capital-raising efforts and strategic plans for BIASURGE offer promising opportunities for growth.
Overall, Sanara MedTech Inc. is positioned to capitalize on its product portfolio and partnerships to drive future success and market expansion.

Sanara MedTech reports robust Q2 growth amidst operational challenges

Sanara MedTech's Q2 2023 performance reflects strong revenue growth and improved financials, despite challenges like slower hiring and supply issues impacting sales.
The company's strategic strengths lie in innovation, market expansion efforts, and a proactive approach to addressing operational challenges for sustained growth.
Opportunities for Sanara MedTech include new product launches, international expansion, and strategic acquisitions to drive future revenue and market competitiveness.

Sanara MedTech (SMTI) posts record Q3 revenue, eyes growth opportunities

Sanara MedTech (SMTI) reported strong financial performance in Q3 with record revenues and improved margins, driven by strategic acquisitions and operational efficiencies.
While facing challenges like supply issues and increased expenses, the company is focused on leveraging new product launches and growth strategies for future success.
Opportunities lie in expanding market presence with innovative products, bundling strategies, and efficient operations to drive growth and enhance customer value.
Overall, Sanara MedTech's commitment to innovation, cost-effectiveness, and market expansion positions it well for long-term success and leadership in the healthcare industry.

Sanara MedTech Inc. reports record revenue, eyes growth through innovation

Sanara MedTech Inc. delivered strong revenue growth in 2023, driven by sales of soft tissue repair products.
While facing profitability challenges, the company's strategic focus on innovation and cost management bodes well for future growth.
Opportunities lie in expanding market presence, product offerings, and strategic partnerships to drive revenue and enhance competitiveness.
Efforts to improve outcomes in chronic wound care and lower costs demonstrate a commitment to long-term sustainability and market leadership.

Sanara MedTech (SMTI) reports record revenue and strategic growth initiatives

Sanara MedTech (SMTI) demonstrated strong financial performance in Q3 2024, with record revenue and positive EBITDA, driven by growth in soft tissue product sales.
Strategic investments in ChemoMouthpiece, LLC, and the upcoming launch of Tissue Health Plus (THP) position the company for future market disruption and revenue expansion.
While challenges exist in the Surgical segment's profitability, Sanara's overall performance and strategic initiatives present opportunities for sustained growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sanara MedTech (SMTI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Sanara MedTech (SMTI) Rating Upgrade to Buy

Sanara MedTech Inc. (NASDAQ:SMTI ) Q3 2024 Earnings Conference Call November 13, 2024 9:00 AM ET Company Participants Ronald Nixon - Executive Chairman and CEO Seth Yon - President of Commercial Michael McNeil - Chief Financial Officer Sam Muppalla - Tissue Health Plus Conference Call Participants Ross Osborn - Cantor Fitzgerald Ian Cassel - MicroCapClub Chris Plahm - Tall Pines Capital John Siedhoff - Twin Oaks Equity Operator Good morning, and welcome to the Sanara MedTech Third Quarter 2024 Earnings Conference Call. The company issued its earnings release yesterday and will post today's supplemental deck on the Investor Relations page on the company's website.

Sanara MedTech Inc. (SMTI) Q3 2024 Earnings Call Transcript

FORT WORTH, TX, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its strategic, operational and financial results for the quarter ended September 30, 2024.

Sanara MedTech Inc. Reports Third Quarter 2024 Results

FORT WORTH, TX, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced details for the release of its results for the quarter ended September 30, 2024. Sanara will issue its earnings release on Tuesday, November 12, 2024, and will host a conference call on Wednesday, November 13, 2024, at 9:00 a.m.

Sanara MedTech Inc. Announces Third Quarter Earnings Release and Conference Call Dates

FORT WORTH, TX, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. -- Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI), a medical technology company focused on improving clinical outcomes and reducing healthcare expenditures in the surgical, chronic wound and skincare markets announced today changes to its Board of Directors (“Board”). After a long tenure of service with the predecessor company and Sanara, Mr. James “Jim” Stuckert has resigned from his position as a director, and Mr. Keith Myers has been appointed to serve as a director on the Board in order to fill the vacancy resulting from Mr. Stuckert's resignation. Mr. Stuckert will continue to serve the Board as Director Emeritus.

Sanara MedTech Inc. Announces Changes to Its Board of Directors

Shares of Sanara MedTech Inc (SMTI, Financial) surged 3.79% in mid-day trading on Oct 2. The stock reached an intraday high of $30.10, up from its previous close of $29.00.

Sanara MedTech Inc (SMTI) Trading 3.79% Higher on Oct 2

SMTI, along with InfuSystem, inked a U.S. distribution agreement with ChemoMouthpiece. Under the agreement, ChemoMouthpiece's oral cryotherapy device will be distributed in cancer centers.

Sanara Stock Gains From New US Distribution Deal With ChemoMouthPiece

FORT WORTH, TX, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on improving clinical outcomes and reducing healthcare expenditures in the surgical, chronic wound and skincare markets, and InfuSystem, Inc. (“InfuSystem”), the operational subsidiary of Sanara's joint venture partner InfuSystem Holdings, Inc., announced today the execution of an exclusive United States distribution agreement with, and minority investment in, ChemoMouthpiece, LLC (“ChemoMouthpiece”).

Sanara MedTech Inc. and InfuSystem Holdings, Inc. Announce Exclusive United States Distribution Agreement with, and Minority Investment in, ChemoMouthpiece, LLC

Sanara MedTech Inc. (SMTI) Q2 2024 Earnings Call Transcript

FORT WORTH, TX, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial results for the quarter ended June 30, 2024.

Sanara MedTech Inc. Announces Second Quarter 2024 Results

FORT WORTH, TX, July 30, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced details for the release of its results for the quarter ended June 30, 2024.

Sanara MedTech Inc. Announces Second Quarter Earnings Release and Conference Call Dates

Sanara MedTech Inc. (NASDAQ:SMTI ) Q1 2024 Earnings Conference Call May 14, 2024 9:00 AM ET Company Participants Callon Nichols - Director of IR Ron Nixon - Executive Chairman Mike McNeil - CFO Seth Yon - President, Commercial Conference Call Participants Ian Cassel - IFCM Operator Greetings, welcome to the Sanara MedTech Inc. First Quarter Results and Business Update Conference Call. At this time all participants are in a listen-only mode.

Sanara MedTech Inc. (SMTI) Q1 2024 Earnings Call Transcript

FORT WORTH, TX, May 13, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial results for the quarter ended March 31, 2024.

Sanara MedTech Inc. Announces First Quarter 2024 Results

FORT WORTH, TX, April 29, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced details for the release of its results for the quarter ended March 31, 2024.

Sanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call Dates

FORT WORTH, TX, April 18, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that it has entered into a $55.0 million non-dilutive term loan agreement with CRG Servicing LLC, an affiliate of CRG LP (“CRG”), a healthcare focused investment fund, to support the Company's growth initiatives in 2024 and 2025.

Sanara MedTech Inc. Announces $55 Million Debt Facility

FORT WORTH, TX, April 05, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer.

Sanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer

Sanara MedTech Inc. (SMTI) Q4 2023 Earnings Call Transcript

FORT WORTH, TX, March 25, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial results for the quarter and full year ended December 31, 2023.

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results

FORT WORTH, TX, March 13, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced details for the release of its results for the quarter and year ended December 31, 2023.

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call Dates

FORT WORTH, TX, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today certain unaudited preliminary results for the fourth quarter and full-year 2023.

Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023

FORT WORTH, TX, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), announced today that is has signed an exclusive license agreement with Tufts University (“Tufts”) to develop and commercialize patented technology covering 18 unique collagen peptides.

Sanara MedTech Inc. Announces Exclusive License Agreement for Patented Collagen Peptides

FORT WORTH, TX, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that the Journal of Surgery has published a retrospective study on CellerateRX® Surgical Powder (“CellerateRX”) titled “Activated Collagen Powder Significantly Reduces Surgical Site Infections in Patients Undergoing Elective Surgery”.

Sanara MedTech Inc. Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX® Surgical Powder) Was Used to Promote Wound Healing

Sanara MedTech Inc. (NASDAQ:SMTI ) Q3 2023 Results Conference Call November 14, 2023 9:00 AM ET Company Participants Callon Nichols - Vice President of Corporate Operations Ron Nixon - Executive Chairman Zach Fleming - Chief Executive Officer Mike McNeil - CFO & Corporate Secretary Conference Call Participants Ross Osborn - Cantor Fitzgerald Ian Cassel - IFCM Niraj Gupta - GCI Partners Operator Greetings, and welcome to the Sanara MedTech Incorporated Third Quarter 2023 Results and Business Update Call. At this time, all participants are in a listen-only mode.

Sanara MedTech Inc. (SMTI) Q3 2023 Earnings Call Transcript

FORT WORTH, TX, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial results for the quarter ended September 30, 2023.

Sanara MedTech Inc. Announces Third Quarter 2023 Results

FORT WORTH, TX, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, wound and skincare markets, announced today the first sale of ALLOCYTE ® Plus Advanced Viable Bone Matrix (“ALLOCYTE Plus” or “ALLOCYTE+”).

News for Sanara MedTech Inc. Stock (SMTI)